Abstracts tagged "Cardiovascular disease"

Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Paras Karmacharya¹, Ravi Shahukhal ², Cynthia Crowson ³, M.Hassan Murad ⁴, Pragya shrestha ⁵, Delamo Bekele ⁶, Kerry Wright ⁴, John Davis ⁴ and Maureen Dubreuil ⁷, ¹Reading Hospital, Mayo Clinic, Rochester, ²Lakes Regional General Hospital, Laconia, NH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic. Rochester, MN, Rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…
Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Kevin Real¹, Michael Duryee ¹, Patrick Opperman ¹, Evan Ryan ¹, Logan Duryee ¹, James O'Dell ², Ted Mikuls ², Daniel Anderson ¹ and Geoffrey Thiele ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…
Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Daniel Li¹, Candace Feldman ¹, Hongshu Guan ¹, Brendan Everett ², Seoyoung C. Kim ³ and Karen Costenbader ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…
Abstract Number: 622 • 2019 ACR/ARP Annual Meeting
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Jean Liew¹, John Reveille ², Henna Sawhney ³, Maria Castillo ³, Benjamin Naovarat ⁴, Susan Heckbert ¹ and Lianne Gensler ⁵, ¹University of Washington, Seattle, WA, ²University of Texas McGovern Medical School, Houston, ³University of California in San Francisco, San Francisco, CA, ⁴University of Texas-McGovern Medical School, Houston, TX, ⁵University San Francisco California, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…
Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Juliana Imgenberg-Kreuz¹, Christopher Sjöwall ², Martina Frodlund ², Iva Gunnarsson ³, Elisabet Svenungsson ⁴ and Dag Leonard ¹, ¹Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Shivani Garg¹, Christie Bartels ¹, Cristina Drenkard ², Gaobin Bao ² and S Sam Lim ², ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Emory University, Atlanta, GA
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…
Abstract Number: 2059 • 2019 ACR/ARP Annual Meeting
Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Dionicio Galarza-Delgado ¹, Jose Azpiri-Lopez ¹, Iris Colunga-Pedraza ¹, Carolina Marlene Martinez-Flores¹, Marielva Castro-Gonzalez ¹, Ileana Cecilia Reynosa-Silva ¹, Karla Paola Cuellar-Calderon ¹ and Raymundo Vera-Pineda ², ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Subjects with rheumatic diseases have an increased risk of cardiovascular (CV) morbimortality. Hypertension (HTN) is a key modifiable risk factor for CV events. A…
Abstract Number: 900 • 2019 ACR/ARP Annual Meeting
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Angelo Gaffo¹, David Calhoun ², Elizabeth Rahn ¹, Suzanne Oparil ², Peng Li ², Tanja Dudenbostel ², David Redden ², Amy Mudano ², Jeffrey Foster ¹, Daniel Feig ², Stephanie Biggers ² and Kenneth Saag ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: An effect of serum urate on vascular endothelium has been postulated as a mechanism for its association with hypertension and cardiovascular disease. Prior studies…
Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Rouhin Sen¹, Sarah Aurit ², Luay Sarsam ³, Osman Bhatty ⁴, Mukund Kumar ¹ and Joseph Nahas ¹, ¹Creighton University Medical Center, Omaha, NE, ²Creighton University Medical Center, Omaha, ³Arnot Health, Elmira, NY, ⁴Montefiore Medical Center Wakefield Campus, Bronx, NY
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Fabio Cacciapaglia¹, Gian Luca Erre ², Garifallia Sakellariou ³, Ombretta Viapiana ⁴, Matteo Piga ⁵, Elena Bartoloni ⁶, Andreina Manfredi ⁷, Sergio Colella ¹, Floriana Castagna ², Giacomo Cafaro ⁸, Martina Dessì ⁵, Marco Fornaro ¹, Alessandro Giollo ⁹, Silvia Grignaschi ¹⁰, Caterina Vacchi ¹¹, Francesca Romana Spinelli ¹², Fabiola Atzeni ¹³ and Elisa Gremese ¹⁴, ¹Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, ³Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴University of Verona, Verona, Italy, ⁵Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁷Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁸Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, ¹⁰Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, ¹¹Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, ¹²Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, ¹³Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ¹⁴Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…
Abstract Number: 923 • 2019 ACR/ARP Annual Meeting
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…
Abstract Number: 2316 • 2019 ACR/ARP Annual Meeting
National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014
Shraddha Jatwani¹, Karan Jatwani ², Bikramjit Bindra ³ and Karan Chugh ¹, ¹St. Vincent Evansville, Evansville, ²Mount Sinai West - St Luke’s Hospital, New York, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Rheumatoid arthritis (RA) has been associated with increased cardiovascular mortality. More intensive treatment with a focus on “treat to target” strategies are being developed,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.